Pharmacological nature of TP receptor mediated contraction in human intrapulmonary artery

Life Sciences

Volumn 59, Issue 24, 1996, Pages 2059-2065

  Jino, Hiroshi ^a   Kurahashi, Kazuyoshi ^a   Usui, Hachiro ^a   Nakata, Youhei ^a   Shimizu, Yoshiharu ^b   Temma, Shinji ^c  

^a KYOTO UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c MITSUBISHI KYOTO HOSPITAL   (Japan)

Author keywords

forskolin; human intrapulmonary artery; nifedipine; nitroglycerin; PLC inhibitor; TXA2 induced contraction

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 15 CYCLOPENTYL 14 OXO 13 AZA 16,17,18,19,20 PENTANORPINANE THROMBOXANE A2; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 9,11 EPITHIO 11,12 METHANOTHROMBOXANE A2; ADENYLATE CYCLASE ACTIVATOR; CALCIUM; DIPHENYLCARBAMIC ACID 4 CARBOXY 2 NITROPHENYL ESTER; DOMITROBAN; EGTAZIC ACID; FORSKOLIN; GLYCERYL TRINITRATE; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; PHOSPHOLIPASE C; PHOSPHOLIPASE C INHIBITOR; PROSTAGLANDIN RECEPTOR; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE A2 RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTERY CONSTRICTION; ARTICLE; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG ARTERY; LUNG CANCER; MALE;

ADULT; AGED; CALCIUM; FEMALE; FORSKOLIN; HUMANS; MALE; MIDDLE AGED; MUSCLE CONTRACTION; NIFEDIPINE; NITROGLYCERIN; PHOSPHOLIPASE C; PULMONARY ARTERY; RECEPTORS, PROSTAGLANDIN; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOXANE A2;

EID: 0030575787     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(96)00559-0     Document Type: Article

References (21)

1. 1. M. HAMBERG, J. SVENSSON and B. SAMUELSSON, Proc. Natl. Acad. Sci. U.S.A. 72 2994-2998 (1975).
2. 2. S.A. KRAFT, S. FUJISHIMA, G.P. McGUIRE, J.S. THOMPSON, T.A., RAFFIN and R.G. PEARL, J. Appl. Physiol. 78 499-504 (1995).
3. 3. J.X. LI, J.R. OLIVER, C.Y. LU and J.B. PHILIPS, Am. J. Med. Sci. 310 103-110 (1995).
4. 4. F. ICHINOSE, C. ADRIE, W.E. HURFORD AND W.M. ZAPOL, J. Appl. Physiol. 78 1288-1295 (1995).
5. 5. F. BERTOLINO, J.P. VALENTIN, M. MAFFRE, B. JOVER, A.M. BESSAC and G.W. JOHN, Arch. Mal. Coeur. Vaiss 87 971-974 (1994).
6. 6. S. FUSE and T. KAMIYA, Circulation 90 2952-2955 (1994).
7. 7. L. FURCI, D.J. FITZGERALD and G. A. FITZGERALD, J. Pharmacol. Exp. Ther. 258 74-81 (1991).
8. 8. T. YAMAGISHI, T. YANAGISAWA and N. TAIRA, Biochem. Biophys. Res. Commun. 187 1517-1522 (1992).
9. 9. U.D. SOHN, K.M. HARNETT, G. PETRIS, J. BEHAR and P. BIANCANI, J. Pharmacol. Exp. Ther. 267 1205-1214 (1993).
10. 10. R. WALENGA, J.Y. VANDERHOEK and M.B. FEINSTEIN, J. Biol. Chem. 255 6024-6027 (1980).
11. 11. K. KURAHASHI, Y. AKIMOTO, H. USUI and H. JINO, Life Sci. 51 695-702 (1992).
12. 12. D.M. LINDEBORG, B.P. KAVANAGH, K. VAN-MEURS and R.G. PEARL, J. Appl. Physiol. 78 341-348 (1995).
13. 13. C.A. LAWSON, A.J. SMERLING, Y. NAKA, D. BURKHOFF, M. L. DICKSTEIN, D.M. STERN and D.J. PINSKY, Am. J. Physiol. 268 H2056-2062 (1995).
14. 14. H. NODA, S. NOSHIMA, H. NAKAZAWA, J. MEYER, D.N. HERNDON, H. REDL, J. FLYNN, L.D. TRABER and D.L. TRABER, Shock 1 291-298 (1994).
15. 15. S.E. HALL, Med. Res. Rev. 11 503-579 (1991).
16. 16. J.Y. JEREMY, D.P. MIKHAILIDIS and P. DANDONA, Eur. J. Pharmacol. 107 259-262 (1985).
17. 17. R. LOUTZENHISER and C. VAN BREEMEN, Am. J. Physiol. 241 C243-C249 (1981).
18. 18. G. W. DORN II., D. SENS, A. CHAIKHOUNI, D. MAIS and P. V. HALUSHKA, Circ. Res. 60 952-956 (1987).
19. 19. L. J. LEWIS, Drugs 43 37-43 (1992).
20. 20. M.A.M.M GOUW, B. WILFFERT, D. WERMELSKIRCHEN and P.A. VAN ZWIETEN, Pharmacology 40 277-287 (1990).
21. 21. T.M. LINCOLN and V. FISHER-SIMPSON, Eur. J. Pharmacol. 101 17-27 (1983).